Nanchang drugmaker selling over-the-counter medicines and health products under household brands through national pharmacy and distributor channels.
Nanchang drugmaker selling over-the-counter medicines and health products under household brands through national pharmacy and distributor channels.
Earns its money from branded over-the-counter medicines, bought without a prescription, sold in volume through distributors and pharmacy chains and kept visible by heavy brand promotion. Traditional Chinese medicines make up a large part of drug sales, and eye drops and cold remedies are the best-known brands. A health-products line is being built beside the drugs.
Moat: narrow (brand, distribution). Long-established OTC brands and a nationwide sales network; little patent protection and heavy advertising reliance.
Headquarters: Nanchang, China
Size Renhe Pharmacy (000650.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.01B, the 2134th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥4.90 on 18 Nov 2026.
Performance Over six months the shares fell 12.0%, against -10.6% for the median peer and -20.0% for the China market (cap-weighted) — 10th lowest of 21 in its peer set.
Growth Revenue fell 7.0% over the last twelve months (peer median +7.7%); the operating margin is 14.3% (peer median 8.7%).
Valuation It trades at 16.9× forward earnings against a peer median of 20.6× (7th cheapest of 15).
Price implies For today's price to make sense, revenue must grow about -11% a year for seven years (Req g). Recent delivered growth is -7%, so the hurdle is -4 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 5.0 points above its cost of capital (7.2% WACC).
Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥3.49B | n/a | CN¥4.05B | CN¥5.00B | CN¥5.12B |
| Revenue growth | — | — | -19% | -2% | — |
| Gross profit | CN¥1.33B | n/a | n/a | CN¥1.78B | CN¥1.78B |
| EBITDA | n/a | n/a | n/a | CN¥1.09B | CN¥1.00B |
| Net income | CN¥386M | n/a | CN¥482M | CN¥567M | CN¥574M |
| Free cash flow | CN¥488M | n/a | n/a | CN¥391M | CN¥1.09B |
| Capital expenditure | CN¥47.8M | n/a | n/a | CN¥187M | CN¥221M |
| Total debt | CN¥2.22M | n/a | n/a | CN¥18.5M | CN¥34.4M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Renhe Pharmacy 000650.SZ | $1.01B | -12% | -7% | 14% | 16.9× | -10.7% |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | $6.59B | +6% | +4% | 14% | 13.2× | -6.2% |
| China Resources Jiangzhong Pharmaceutical 600750.SS | $2.27B | +4% | -10% | 24% | 16.5× | -1.9% |
| Chongqing Taiji Industry (Group) 600129.SS | $982M | -20% | -4% | 2% | 69.8× | n/a |
| Yunnan Baiyao 000538.SZ | $15.0B | +11% | +5% | 11% | 18.3× | -0.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 000650.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.5% | -6.0% | 8th highest of 21 |
| 6-month return | -12.0% | -10.6% | 10th lowest of 21 |
| Distance from 52-week high | -23.6% | -32.4% | 6th highest of 21 |
| Revenue growth (TTM) | -7.0% | +7.7% | 3rd lowest of 19 |
| Operating margin | 14.3% | 8.7% | 7th highest of 19 |
| Forward P/E | 16.9× | 20.6× | 7th cheapest of 15 |
| Growth the price implies (Req g, 7 yrs) | -10.7% | 4.3% | least demanding of 14 |
| Growth delivered (Del g) | -7.0% | +7.7% | 3rd lowest of 14 |
| Hurdle (Req g minus delivered) | -3.6 pp | -3.3 pp | 7th least demanding of 14 |
| ROIC minus cost of capital | +5.0 pp | +0.1 pp | 5th highest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Renhe Pharmacy 000650.SZ | China | $1.01B | -12% | -7% | 14% | 16.9× | -10.7% | -7.0% |
| SAWAI 4887.T | Japan | $1.01B | -18% | +2% | 9% | 12.0× | n/a | n/a |
| Zhejiang Tianyu Pharmaceutical 300702.SZ | China | $1.02B | +1% | +27% | 4% | 21.4× | 4.3% | +3.5% |
| Jiangxi Fushine Pharmaceutical 300497.SZ | China | $1.02B | -23% | +103% | 24% | 9.9× | 7.5% | -4.5% |
| Shanghai Yizhong Pharmaceutical 688091.SS | China | $1.00B | -49% | +32% | 14% | n/a | n/a | n/a |
| Chengdu Easton Biopharmaceuticals 688513.SS | China | $1.03B | -33% | -2% | 13% | 24.6× | 4.4% | +7.7% |
| Aurisco Pharmaceutical 605116.SS | China | $1.00B | -23% | +3% | 25% | 13.6× | -2.0% | +18.7% |
| Shanghai InnoStar Bio-tech 688710.SS | China | $1,000M | +17% | +24% | 6% | 59.3× | 12.7% | +19.4% |
| Towa Pharmaceutical 4553.T | Japan | $1.03B | -10% | +7% | 9% | 7.7× | -0.3% | +12.1% |
| Sunflower Pharmaceutical 002737.SZ | China | $1.04B | -11% | +31% | -7% | 4.7× | -6.5% | -7.7% |
| Jiangsu Kanion Pharmaceutical 600557.SS | China | $989M | -9% | +8% | 7% | 19.8× | 2.3% | +1.8% |
| Savara SVRA | United States | $1.04B | -7% | n/a | n/a | n/a | n/a | n/a |
| Basilea Pharmaceutica BSLN.SW | Switzerland | $1.04B | +33% | +5% | 24% | 10.5× | -5.6% | +12.7% |
| Aarti Pharmalabs AARTIPHARM.NS | India | $984M | +44% | +13% | 18% | n/a | n/a | n/a |
| InventisBio 688382.SS | China | $982M | -47% | -61% | -563% | n/a | 6.5% | -60.6% |
| Chongqing Taiji Industry (Group) 600129.SS | China | $982M | -20% | -4% | 2% | 69.8× | n/a | n/a |
| Shandong Lukang Pharmaceutical 600789.SS | China | $1.05B | -18% | -7% | 3% | n/a | 2.5% | +6.5% |
| Seaport Therapeutics SPTX | United States | $980M | +16% | n/a | n/a | n/a | n/a | n/a |
| Blue Jet Healthcare BLUEJET.NS | India | $1.05B | +19% | -7% | 28% | 30.6× | 40.8% | +13.8% |
| Procter & Gamble Health PGHL.NS | India | $979M | +3% | +13% | 31% | 24.5× | 5.6% | +9.3% |
| Everest Medicines 1952.HK | Hong Kong | $1.05B | -20% | +193% | -5% | 23.2× | n/a | n/a |